PortalPublikationenRadical prostatectomy neutralizes obesity-driven risk of pro...

Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression

Standard

Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. / Schiffmann, Jonas; Salomon, Georg; Tilki, Derya; Budäus, Lars; Karakiewicz, Pierre I; Leyh-Bannurah, Sami-Ramzi; Pompe, Raisa S; Haese, Alexander; Heinzer, Hans; Huland, Hartwig; Graefen, Markus; Tennstedt, Pierre.

in: UROL ONCOL-SEMIN ORI, Jahrgang 35, Nr. 5, 05.2017, S. 243-249.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schiffmann, J, Salomon, G, Tilki, D, Budäus, L, Karakiewicz, PI, Leyh-Bannurah, S-R, Pompe, RS, Haese, A, Heinzer, H, Huland, H, Graefen, M & Tennstedt, P 2017, 'Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression', UROL ONCOL-SEMIN ORI, Jg. 35, Nr. 5, S. 243-249. https://doi.org/10.1016/j.urolonc.2016.12.014

APA

Schiffmann, J., Salomon, G., Tilki, D., Budäus, L., Karakiewicz, P. I., Leyh-Bannurah, S-R., Pompe, R. S., Haese, A., Heinzer, H., Huland, H., Graefen, M., & Tennstedt, P. (2017). Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. UROL ONCOL-SEMIN ORI, 35(5), 243-249. https://doi.org/10.1016/j.urolonc.2016.12.014

Vancouver

Schiffmann J, Salomon G, Tilki D, Budäus L, Karakiewicz PI, Leyh-Bannurah S-R et al. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. UROL ONCOL-SEMIN ORI. 2017 Mai;35(5):243-249. https://doi.org/10.1016/j.urolonc.2016.12.014

Bibtex

@article{1b293838b57b4cb69f243f09303bd4f3,
title = "Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression",
abstract = "INTRODUCTION: Obesity negatively affects several prostate cancer (PCa) outcomes, including mortality to PCa. However, the validity of several such associations is still under debate, including its effect on pathological stage at radical prostatectomy (RP) and subsequent biochemical recurrence (BCR), which represents the focus of this study.METHODS: We relied on patients with PCa treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable logistic regression analyses tested for association between obesity and non-organ-confined disease (≥pT3 or pN1). Second, multivariable Cox regression analyses examined obesity effect on BCR. Last, in a propensity score-matched cohort, Kaplan-Meier analyses assessed BCR-free survival according to body mass index (kg/m2) (BMI) strata (≥30 vs.<25).RESULTS: Of 16,014 individuals, 2,403 (15%) men were obese (BMI≥30). Median follow-up was 36.4 months (interquartile range: 13.3-60.8). Obese patients were more likely to harbor non-organ-confined disease at final pathology (odds ratio = 1.27; 95% CI: 1.13-1.43; P<0.001) but did not have higher BCR rates (hazard ratio = 0.98; 95% CI: 0.86-1.11; P = 0.7). Similarly, BCR-free survival was not different between obese and nonobese men, after propensity score matching (log rank P = 0.9).CONCLUSION: Obesity (BMI ≥30) might predispose to higher rates of non-organ-confined disease at RP. However, obesity was not an independent predictor of BCR after surgery. Consequently, the unfavorable effect of obesity on PCa might be limited to local spread of the disease and might be neutralized after RP.",
keywords = "Aged, Disease Progression, Disease-Free Survival, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasm, Residual, Obesity, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Journal Article",
author = "Jonas Schiffmann and Georg Salomon and Derya Tilki and Lars Bud{\"a}us and Karakiewicz, {Pierre I} and Sami-Ramzi Leyh-Bannurah and Pompe, {Raisa S} and Alexander Haese and Hans Heinzer and Hartwig Huland and Markus Graefen and Pierre Tennstedt",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2017",
month = may,
doi = "10.1016/j.urolonc.2016.12.014",
language = "English",
volume = "35",
pages = "243--249",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression

AU - Schiffmann, Jonas

AU - Salomon, Georg

AU - Tilki, Derya

AU - Budäus, Lars

AU - Karakiewicz, Pierre I

AU - Leyh-Bannurah, Sami-Ramzi

AU - Pompe, Raisa S

AU - Haese, Alexander

AU - Heinzer, Hans

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Tennstedt, Pierre

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2017/5

Y1 - 2017/5

N2 - INTRODUCTION: Obesity negatively affects several prostate cancer (PCa) outcomes, including mortality to PCa. However, the validity of several such associations is still under debate, including its effect on pathological stage at radical prostatectomy (RP) and subsequent biochemical recurrence (BCR), which represents the focus of this study.METHODS: We relied on patients with PCa treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable logistic regression analyses tested for association between obesity and non-organ-confined disease (≥pT3 or pN1). Second, multivariable Cox regression analyses examined obesity effect on BCR. Last, in a propensity score-matched cohort, Kaplan-Meier analyses assessed BCR-free survival according to body mass index (kg/m2) (BMI) strata (≥30 vs.<25).RESULTS: Of 16,014 individuals, 2,403 (15%) men were obese (BMI≥30). Median follow-up was 36.4 months (interquartile range: 13.3-60.8). Obese patients were more likely to harbor non-organ-confined disease at final pathology (odds ratio = 1.27; 95% CI: 1.13-1.43; P<0.001) but did not have higher BCR rates (hazard ratio = 0.98; 95% CI: 0.86-1.11; P = 0.7). Similarly, BCR-free survival was not different between obese and nonobese men, after propensity score matching (log rank P = 0.9).CONCLUSION: Obesity (BMI ≥30) might predispose to higher rates of non-organ-confined disease at RP. However, obesity was not an independent predictor of BCR after surgery. Consequently, the unfavorable effect of obesity on PCa might be limited to local spread of the disease and might be neutralized after RP.

AB - INTRODUCTION: Obesity negatively affects several prostate cancer (PCa) outcomes, including mortality to PCa. However, the validity of several such associations is still under debate, including its effect on pathological stage at radical prostatectomy (RP) and subsequent biochemical recurrence (BCR), which represents the focus of this study.METHODS: We relied on patients with PCa treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable logistic regression analyses tested for association between obesity and non-organ-confined disease (≥pT3 or pN1). Second, multivariable Cox regression analyses examined obesity effect on BCR. Last, in a propensity score-matched cohort, Kaplan-Meier analyses assessed BCR-free survival according to body mass index (kg/m2) (BMI) strata (≥30 vs.<25).RESULTS: Of 16,014 individuals, 2,403 (15%) men were obese (BMI≥30). Median follow-up was 36.4 months (interquartile range: 13.3-60.8). Obese patients were more likely to harbor non-organ-confined disease at final pathology (odds ratio = 1.27; 95% CI: 1.13-1.43; P<0.001) but did not have higher BCR rates (hazard ratio = 0.98; 95% CI: 0.86-1.11; P = 0.7). Similarly, BCR-free survival was not different between obese and nonobese men, after propensity score matching (log rank P = 0.9).CONCLUSION: Obesity (BMI ≥30) might predispose to higher rates of non-organ-confined disease at RP. However, obesity was not an independent predictor of BCR after surgery. Consequently, the unfavorable effect of obesity on PCa might be limited to local spread of the disease and might be neutralized after RP.

KW - Aged

KW - Disease Progression

KW - Disease-Free Survival

KW - Humans

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Invasiveness

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Neoplasm, Residual

KW - Obesity

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Journal Article

U2 - 10.1016/j.urolonc.2016.12.014

DO - 10.1016/j.urolonc.2016.12.014

M3 - SCORING: Journal article

C2 - 28161322

VL - 35

SP - 243

EP - 249

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 5

ER -